Overview
Synolo Therapeutics develops early-stage, logic-gated immunotherapies for cancer and autoimmune diseases using a proprietary drug discovery platform to build a pipeline of conditionally active therapies designed to be highly effective and safer than current treatments. Therapies are activated only under specific biological conditions (logic gates), guiding immune responses to diseased tissue and reducing off-target effects. It differentiates itself by combining a proprietary discovery platform with a focus on safety and a distinct pipeline in oncology and autoimmunity. Its goal is to deliver differentiated, conditionally active immunotherapies that outperform existing options in safety and efficacy.
Work here?Claim your company
Simplify's take
What believers are saying
- Synolo’s website updated July 8, 2026, signaling continued active development.
- LinkedIn and job posts show hiring for protein science and biologics discovery in 2026.
- RA Ventures backstopping gives Synolo recruiting, capital access, and scientific credibility.
What critics are saying
- Synolo posted only one job on its careers board in October 2026.
- No clinical trial, partnership, or financing announcement surfaced by November 2026.
- If Synolo cannot generate differentiated preclinical data fast, RA Capital can quietly starve it.
What makes Synolo Therapeutics unique
- RA Ventures launched Synolo in 2023 inside RA Capital’s company-creation engine.
- Synolo targets cancer and autoimmune disease with logic-gated, conditionally active immunotherapies.
- Its platform emphasizes computational protein design and multi-specific biologics, not single-target antibodies.
Help us improve and share your feedback! Did you find this helpful?